nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—skin cancer—melanoma	0.654	1	CtDrD
Imiquimod—CYP1A2—Carmustine—melanoma	0.05	0.27	CbGbCtD
Imiquimod—CYP1A2—Vemurafenib—melanoma	0.0396	0.213	CbGbCtD
Imiquimod—CYP3A4—Temozolomide—melanoma	0.0378	0.204	CbGbCtD
Imiquimod—CYP1A2—Dacarbazine—melanoma	0.0303	0.163	CbGbCtD
Imiquimod—CYP3A4—Vemurafenib—melanoma	0.0207	0.112	CbGbCtD
Imiquimod—CYP3A4—Docetaxel—melanoma	0.00711	0.0383	CbGbCtD
Imiquimod—Hepatobiliary disease—Temozolomide—melanoma	0.000157	0.00175	CcSEcCtD
Imiquimod—Alopecia—Bleomycin—melanoma	0.000156	0.00174	CcSEcCtD
Imiquimod—Erythema multiforme—Dactinomycin—melanoma	0.000156	0.00174	CcSEcCtD
Imiquimod—Sinusitis—Temozolomide—melanoma	0.000156	0.00174	CcSEcCtD
Imiquimod—Haemoglobin—Carmustine—melanoma	0.000155	0.00173	CcSEcCtD
Imiquimod—Haemorrhage—Carmustine—melanoma	0.000154	0.00172	CcSEcCtD
Imiquimod—Erythema—Bleomycin—melanoma	0.000154	0.00171	CcSEcCtD
Imiquimod—Flushing—Dactinomycin—melanoma	0.000153	0.0017	CcSEcCtD
Imiquimod—Hypersensitivity—Vemurafenib—melanoma	0.000153	0.0017	CcSEcCtD
Imiquimod—Connective tissue disorder—Carmustine—melanoma	0.000152	0.00169	CcSEcCtD
Imiquimod—Atrial fibrillation—Docetaxel—melanoma	0.000151	0.00168	CcSEcCtD
Imiquimod—Haemoglobin—Temozolomide—melanoma	0.00015	0.00167	CcSEcCtD
Imiquimod—Haemorrhage—Temozolomide—melanoma	0.000149	0.00166	CcSEcCtD
Imiquimod—Asthenia—Vemurafenib—melanoma	0.000149	0.00166	CcSEcCtD
Imiquimod—Visual impairment—Carmustine—melanoma	0.000149	0.00166	CcSEcCtD
Imiquimod—Pharyngitis—Temozolomide—melanoma	0.000148	0.00165	CcSEcCtD
Imiquimod—Chills—Dactinomycin—melanoma	0.000148	0.00165	CcSEcCtD
Imiquimod—Urinary tract disorder—Temozolomide—melanoma	0.000147	0.00164	CcSEcCtD
Imiquimod—Cardiac failure—Docetaxel—melanoma	0.000147	0.00164	CcSEcCtD
Imiquimod—Pruritus—Vemurafenib—melanoma	0.000147	0.00163	CcSEcCtD
Imiquimod—Connective tissue disorder—Temozolomide—melanoma	0.000146	0.00163	CcSEcCtD
Imiquimod—Lethargy—Docetaxel—melanoma	0.000146	0.00163	CcSEcCtD
Imiquimod—Urethral disorder—Temozolomide—melanoma	0.000146	0.00163	CcSEcCtD
Imiquimod—Alopecia—Dactinomycin—melanoma	0.000146	0.00162	CcSEcCtD
Imiquimod—Eye disorder—Carmustine—melanoma	0.000144	0.00161	CcSEcCtD
Imiquimod—Visual impairment—Temozolomide—melanoma	0.000144	0.0016	CcSEcCtD
Imiquimod—Erythema—Dactinomycin—melanoma	0.000143	0.0016	CcSEcCtD
Imiquimod—Pain in extremity—Docetaxel—melanoma	0.000143	0.0016	CcSEcCtD
Imiquimod—Flushing—Carmustine—melanoma	0.000143	0.00159	CcSEcCtD
Imiquimod—Ill-defined disorder—Bleomycin—melanoma	0.000143	0.00159	CcSEcCtD
Imiquimod—Diarrhoea—Vemurafenib—melanoma	0.000142	0.00158	CcSEcCtD
Imiquimod—Migraine—Docetaxel—melanoma	0.000141	0.00157	CcSEcCtD
Imiquimod—Erythema multiforme—Temozolomide—melanoma	0.000141	0.00157	CcSEcCtD
Imiquimod—Eye disorder—Temozolomide—melanoma	0.000139	0.00155	CcSEcCtD
Imiquimod—Tinnitus—Temozolomide—melanoma	0.000139	0.00155	CcSEcCtD
Imiquimod—Malaise—Bleomycin—melanoma	0.000139	0.00155	CcSEcCtD
Imiquimod—Flushing—Temozolomide—melanoma	0.000138	0.00154	CcSEcCtD
Imiquimod—Arrhythmia—Carmustine—melanoma	0.000138	0.00153	CcSEcCtD
Imiquimod—Dizziness—Vemurafenib—melanoma	0.000137	0.00153	CcSEcCtD
Imiquimod—Alopecia—Carmustine—melanoma	0.000136	0.00152	CcSEcCtD
Imiquimod—Angiopathy—Temozolomide—melanoma	0.000135	0.00151	CcSEcCtD
Imiquimod—Mental disorder—Carmustine—melanoma	0.000135	0.00151	CcSEcCtD
Imiquimod—Immune system disorder—Temozolomide—melanoma	0.000135	0.0015	CcSEcCtD
Imiquimod—Mediastinal disorder—Temozolomide—melanoma	0.000134	0.0015	CcSEcCtD
Imiquimod—Malnutrition—Carmustine—melanoma	0.000134	0.0015	CcSEcCtD
Imiquimod—Erythema—Carmustine—melanoma	0.000134	0.0015	CcSEcCtD
Imiquimod—Cough—Bleomycin—melanoma	0.000134	0.0015	CcSEcCtD
Imiquimod—Chills—Temozolomide—melanoma	0.000134	0.00149	CcSEcCtD
Imiquimod—Ill-defined disorder—Dactinomycin—melanoma	0.000133	0.00148	CcSEcCtD
Imiquimod—Vomiting—Vemurafenib—melanoma	0.000132	0.00147	CcSEcCtD
Imiquimod—Alopecia—Temozolomide—melanoma	0.000132	0.00147	CcSEcCtD
Imiquimod—Chest pain—Bleomycin—melanoma	0.000131	0.00146	CcSEcCtD
Imiquimod—Myalgia—Bleomycin—melanoma	0.000131	0.00146	CcSEcCtD
Imiquimod—Rash—Vemurafenib—melanoma	0.000131	0.00146	CcSEcCtD
Imiquimod—Mental disorder—Temozolomide—melanoma	0.000131	0.00145	CcSEcCtD
Imiquimod—Dermatitis—Vemurafenib—melanoma	0.000131	0.00145	CcSEcCtD
Imiquimod—Back pain—Carmustine—melanoma	0.00013	0.00145	CcSEcCtD
Imiquimod—Headache—Vemurafenib—melanoma	0.00013	0.00145	CcSEcCtD
Imiquimod—Malnutrition—Temozolomide—melanoma	0.00013	0.00145	CcSEcCtD
Imiquimod—Erythema—Temozolomide—melanoma	0.00013	0.00145	CcSEcCtD
Imiquimod—Breast disorder—Docetaxel—melanoma	0.000129	0.00144	CcSEcCtD
Imiquimod—Discomfort—Bleomycin—melanoma	0.000129	0.00144	CcSEcCtD
Imiquimod—Malaise—Dactinomycin—melanoma	0.000129	0.00144	CcSEcCtD
Imiquimod—Oedema—Bleomycin—melanoma	0.000126	0.0014	CcSEcCtD
Imiquimod—Back pain—Temozolomide—melanoma	0.000126	0.0014	CcSEcCtD
Imiquimod—Infection—Bleomycin—melanoma	0.000125	0.00139	CcSEcCtD
Imiquimod—Agitation—Carmustine—melanoma	0.000123	0.00137	CcSEcCtD
Imiquimod—Nausea—Vemurafenib—melanoma	0.000123	0.00137	CcSEcCtD
Imiquimod—Myalgia—Dactinomycin—melanoma	0.000122	0.00136	CcSEcCtD
Imiquimod—Discomfort—Dactinomycin—melanoma	0.000121	0.00134	CcSEcCtD
Imiquimod—Ill-defined disorder—Temozolomide—melanoma	0.00012	0.00134	CcSEcCtD
Imiquimod—Anorexia—Bleomycin—melanoma	0.00012	0.00133	CcSEcCtD
Imiquimod—Agitation—Temozolomide—melanoma	0.000119	0.00133	CcSEcCtD
Imiquimod—Angioedema—Temozolomide—melanoma	0.000119	0.00132	CcSEcCtD
Imiquimod—Pancytopenia—Docetaxel—melanoma	0.000118	0.00131	CcSEcCtD
Imiquimod—Oedema—Dactinomycin—melanoma	0.000117	0.0013	CcSEcCtD
Imiquimod—Malaise—Temozolomide—melanoma	0.000117	0.0013	CcSEcCtD
Imiquimod—Convulsion—Carmustine—melanoma	0.000116	0.0013	CcSEcCtD
Imiquimod—Infection—Dactinomycin—melanoma	0.000116	0.0013	CcSEcCtD
Imiquimod—Hypertension—Carmustine—melanoma	0.000116	0.00129	CcSEcCtD
Imiquimod—Palpitations—Temozolomide—melanoma	0.000115	0.00128	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Bleomycin—melanoma	0.000114	0.00127	CcSEcCtD
Imiquimod—Chest pain—Carmustine—melanoma	0.000114	0.00127	CcSEcCtD
Imiquimod—Myalgia—Carmustine—melanoma	0.000114	0.00127	CcSEcCtD
Imiquimod—Anxiety—Carmustine—melanoma	0.000114	0.00127	CcSEcCtD
Imiquimod—Cough—Temozolomide—melanoma	0.000113	0.00126	CcSEcCtD
Imiquimod—Paraesthesia—Bleomycin—melanoma	0.000113	0.00126	CcSEcCtD
Imiquimod—Convulsion—Temozolomide—melanoma	0.000112	0.00125	CcSEcCtD
Imiquimod—Hypertension—Temozolomide—melanoma	0.000112	0.00125	CcSEcCtD
Imiquimod—Dyspnoea—Bleomycin—melanoma	0.000112	0.00125	CcSEcCtD
Imiquimod—Anorexia—Dactinomycin—melanoma	0.000112	0.00124	CcSEcCtD
Imiquimod—Myalgia—Temozolomide—melanoma	0.00011	0.00123	CcSEcCtD
Imiquimod—Arthralgia—Temozolomide—melanoma	0.00011	0.00123	CcSEcCtD
Imiquimod—Infestation—Docetaxel—melanoma	0.00011	0.00123	CcSEcCtD
Imiquimod—Infestation NOS—Docetaxel—melanoma	0.00011	0.00123	CcSEcCtD
Imiquimod—Anxiety—Temozolomide—melanoma	0.00011	0.00123	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00011	0.00122	CcSEcCtD
Imiquimod—Oedema—Carmustine—melanoma	0.00011	0.00122	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000109	0.00122	CcSEcCtD
Imiquimod—Discomfort—Temozolomide—melanoma	0.000109	0.00122	CcSEcCtD
Imiquimod—Decreased appetite—Bleomycin—melanoma	0.000109	0.00122	CcSEcCtD
Imiquimod—Infection—Carmustine—melanoma	0.000109	0.00121	CcSEcCtD
Imiquimod—Acute coronary syndrome—Docetaxel—melanoma	0.000109	0.00121	CcSEcCtD
Imiquimod—Myocardial infarction—Docetaxel—melanoma	0.000108	0.00121	CcSEcCtD
Imiquimod—Neuropathy peripheral—Docetaxel—melanoma	0.000108	0.00121	CcSEcCtD
Imiquimod—Dry mouth—Temozolomide—melanoma	0.000108	0.0012	CcSEcCtD
Imiquimod—Pain—Bleomycin—melanoma	0.000107	0.0012	CcSEcCtD
Imiquimod—Conjunctivitis—Docetaxel—melanoma	0.000107	0.0012	CcSEcCtD
Imiquimod—Tachycardia—Carmustine—melanoma	0.000107	0.00119	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000107	0.00119	CcSEcCtD
Imiquimod—Oedema—Temozolomide—melanoma	0.000106	0.00118	CcSEcCtD
Imiquimod—Infection—Temozolomide—melanoma	0.000105	0.00117	CcSEcCtD
Imiquimod—Anorexia—Carmustine—melanoma	0.000104	0.00116	CcSEcCtD
Imiquimod—Hepatobiliary disease—Docetaxel—melanoma	0.000104	0.00116	CcSEcCtD
Imiquimod—Nervous system disorder—Temozolomide—melanoma	0.000104	0.00116	CcSEcCtD
Imiquimod—Feeling abnormal—Bleomycin—melanoma	0.000103	0.00115	CcSEcCtD
Imiquimod—Skin disorder—Temozolomide—melanoma	0.000103	0.00115	CcSEcCtD
Imiquimod—Hyperhidrosis—Temozolomide—melanoma	0.000102	0.00114	CcSEcCtD
Imiquimod—Decreased appetite—Dactinomycin—melanoma	0.000102	0.00113	CcSEcCtD
Imiquimod—Fatigue—Dactinomycin—melanoma	0.000101	0.00112	CcSEcCtD
Imiquimod—Anorexia—Temozolomide—melanoma	0.000101	0.00112	CcSEcCtD
Imiquimod—Pain—Dactinomycin—melanoma	0.0001	0.00112	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Carmustine—melanoma	9.98e-05	0.00111	CcSEcCtD
Imiquimod—Urticaria—Bleomycin—melanoma	9.97e-05	0.00111	CcSEcCtD
Imiquimod—Haemoglobin—Docetaxel—melanoma	9.96e-05	0.00111	CcSEcCtD
Imiquimod—Rhinitis—Docetaxel—melanoma	9.94e-05	0.00111	CcSEcCtD
Imiquimod—Body temperature increased—Bleomycin—melanoma	9.92e-05	0.00111	CcSEcCtD
Imiquimod—Haemorrhage—Docetaxel—melanoma	9.91e-05	0.0011	CcSEcCtD
Imiquimod—Insomnia—Carmustine—melanoma	9.91e-05	0.0011	CcSEcCtD
Imiquimod—Paraesthesia—Carmustine—melanoma	9.84e-05	0.0011	CcSEcCtD
Imiquimod—Pharyngitis—Docetaxel—melanoma	9.84e-05	0.0011	CcSEcCtD
Imiquimod—Urinary tract disorder—Docetaxel—melanoma	9.79e-05	0.00109	CcSEcCtD
Imiquimod—Dyspnoea—Carmustine—melanoma	9.77e-05	0.00109	CcSEcCtD
Imiquimod—Somnolence—Carmustine—melanoma	9.74e-05	0.00109	CcSEcCtD
Imiquimod—Connective tissue disorder—Docetaxel—melanoma	9.74e-05	0.00109	CcSEcCtD
Imiquimod—Urethral disorder—Docetaxel—melanoma	9.72e-05	0.00108	CcSEcCtD
Imiquimod—Feeling abnormal—Dactinomycin—melanoma	9.65e-05	0.00107	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Temozolomide—melanoma	9.65e-05	0.00107	CcSEcCtD
Imiquimod—Insomnia—Temozolomide—melanoma	9.58e-05	0.00107	CcSEcCtD
Imiquimod—Gastrointestinal pain—Dactinomycin—melanoma	9.57e-05	0.00107	CcSEcCtD
Imiquimod—Visual impairment—Docetaxel—melanoma	9.55e-05	0.00106	CcSEcCtD
Imiquimod—Decreased appetite—Carmustine—melanoma	9.53e-05	0.00106	CcSEcCtD
Imiquimod—Paraesthesia—Temozolomide—melanoma	9.51e-05	0.00106	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Carmustine—melanoma	9.46e-05	0.00105	CcSEcCtD
Imiquimod—Dyspnoea—Temozolomide—melanoma	9.44e-05	0.00105	CcSEcCtD
Imiquimod—Somnolence—Temozolomide—melanoma	9.41e-05	0.00105	CcSEcCtD
Imiquimod—Erythema multiforme—Docetaxel—melanoma	9.37e-05	0.00104	CcSEcCtD
Imiquimod—Pain—Carmustine—melanoma	9.37e-05	0.00104	CcSEcCtD
Imiquimod—Dyspepsia—Temozolomide—melanoma	9.32e-05	0.00104	CcSEcCtD
Imiquimod—Eye disorder—Docetaxel—melanoma	9.26e-05	0.00103	CcSEcCtD
Imiquimod—Body temperature increased—Dactinomycin—melanoma	9.26e-05	0.00103	CcSEcCtD
Imiquimod—Abdominal pain—Dactinomycin—melanoma	9.26e-05	0.00103	CcSEcCtD
Imiquimod—Hypersensitivity—Bleomycin—melanoma	9.25e-05	0.00103	CcSEcCtD
Imiquimod—Decreased appetite—Temozolomide—melanoma	9.21e-05	0.00103	CcSEcCtD
Imiquimod—Flushing—Docetaxel—melanoma	9.2e-05	0.00102	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Temozolomide—melanoma	9.14e-05	0.00102	CcSEcCtD
Imiquimod—Fatigue—Temozolomide—melanoma	9.13e-05	0.00102	CcSEcCtD
Imiquimod—Pain—Temozolomide—melanoma	9.06e-05	0.00101	CcSEcCtD
Imiquimod—Feeling abnormal—Carmustine—melanoma	9.03e-05	0.00101	CcSEcCtD
Imiquimod—Asthenia—Bleomycin—melanoma	9.01e-05	0.001	CcSEcCtD
Imiquimod—Angiopathy—Docetaxel—melanoma	8.99e-05	0.001	CcSEcCtD
Imiquimod—Gastrointestinal pain—Carmustine—melanoma	8.96e-05	0.000998	CcSEcCtD
Imiquimod—Immune system disorder—Docetaxel—melanoma	8.95e-05	0.000997	CcSEcCtD
Imiquimod—Mediastinal disorder—Docetaxel—melanoma	8.93e-05	0.000995	CcSEcCtD
Imiquimod—Chills—Docetaxel—melanoma	8.89e-05	0.000991	CcSEcCtD
Imiquimod—Pruritus—Bleomycin—melanoma	8.88e-05	0.000989	CcSEcCtD
Imiquimod—Arrhythmia—Docetaxel—melanoma	8.86e-05	0.000986	CcSEcCtD
Imiquimod—Alopecia—Docetaxel—melanoma	8.76e-05	0.000976	CcSEcCtD
Imiquimod—Feeling abnormal—Temozolomide—melanoma	8.73e-05	0.000972	CcSEcCtD
Imiquimod—Mental disorder—Docetaxel—melanoma	8.68e-05	0.000967	CcSEcCtD
Imiquimod—Body temperature increased—Carmustine—melanoma	8.66e-05	0.000965	CcSEcCtD
Imiquimod—Abdominal pain—Carmustine—melanoma	8.66e-05	0.000965	CcSEcCtD
Imiquimod—Gastrointestinal pain—Temozolomide—melanoma	8.66e-05	0.000965	CcSEcCtD
Imiquimod—Malnutrition—Docetaxel—melanoma	8.63e-05	0.000961	CcSEcCtD
Imiquimod—Erythema—Docetaxel—melanoma	8.63e-05	0.000961	CcSEcCtD
Imiquimod—Hypersensitivity—Dactinomycin—melanoma	8.63e-05	0.000961	CcSEcCtD
Imiquimod—Urticaria—Temozolomide—melanoma	8.41e-05	0.000937	CcSEcCtD
Imiquimod—Asthenia—Dactinomycin—melanoma	8.4e-05	0.000936	CcSEcCtD
Imiquimod—Abdominal pain—Temozolomide—melanoma	8.37e-05	0.000933	CcSEcCtD
Imiquimod—Body temperature increased—Temozolomide—melanoma	8.37e-05	0.000933	CcSEcCtD
Imiquimod—Back pain—Docetaxel—melanoma	8.35e-05	0.00093	CcSEcCtD
Imiquimod—Hypersensitivity—Carmustine—melanoma	8.07e-05	0.000899	CcSEcCtD
Imiquimod—Diarrhoea—Dactinomycin—melanoma	8.01e-05	0.000892	CcSEcCtD
Imiquimod—Vomiting—Bleomycin—melanoma	7.98e-05	0.000889	CcSEcCtD
Imiquimod—Rash—Bleomycin—melanoma	7.92e-05	0.000882	CcSEcCtD
Imiquimod—Dermatitis—Bleomycin—melanoma	7.91e-05	0.000881	CcSEcCtD
Imiquimod—Asthenia—Carmustine—melanoma	7.86e-05	0.000876	CcSEcCtD
Imiquimod—Hypersensitivity—Temozolomide—melanoma	7.8e-05	0.000869	CcSEcCtD
Imiquimod—Syncope—Docetaxel—melanoma	7.74e-05	0.000862	CcSEcCtD
Imiquimod—Palpitations—Docetaxel—melanoma	7.63e-05	0.000849	CcSEcCtD
Imiquimod—Asthenia—Temozolomide—melanoma	7.6e-05	0.000846	CcSEcCtD
Imiquimod—Loss of consciousness—Docetaxel—melanoma	7.58e-05	0.000845	CcSEcCtD
Imiquimod—Cough—Docetaxel—melanoma	7.53e-05	0.000839	CcSEcCtD
Imiquimod—Diarrhoea—Carmustine—melanoma	7.5e-05	0.000835	CcSEcCtD
Imiquimod—Pruritus—Temozolomide—melanoma	7.49e-05	0.000835	CcSEcCtD
Imiquimod—Convulsion—Docetaxel—melanoma	7.48e-05	0.000833	CcSEcCtD
Imiquimod—Nausea—Bleomycin—melanoma	7.46e-05	0.000831	CcSEcCtD
Imiquimod—Hypertension—Docetaxel—melanoma	7.45e-05	0.00083	CcSEcCtD
Imiquimod—Vomiting—Dactinomycin—melanoma	7.44e-05	0.000829	CcSEcCtD
Imiquimod—Rash—Dactinomycin—melanoma	7.38e-05	0.000822	CcSEcCtD
Imiquimod—Arthralgia—Docetaxel—melanoma	7.35e-05	0.000818	CcSEcCtD
Imiquimod—Chest pain—Docetaxel—melanoma	7.35e-05	0.000818	CcSEcCtD
Imiquimod—Myalgia—Docetaxel—melanoma	7.35e-05	0.000818	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	7.3e-05	0.000813	CcSEcCtD
Imiquimod—Dizziness—Carmustine—melanoma	7.25e-05	0.000807	CcSEcCtD
Imiquimod—Diarrhoea—Temozolomide—melanoma	7.25e-05	0.000807	CcSEcCtD
Imiquimod—Dry mouth—Docetaxel—melanoma	7.19e-05	0.0008	CcSEcCtD
Imiquimod—Oedema—Docetaxel—melanoma	7.04e-05	0.000785	CcSEcCtD
Imiquimod—Dizziness—Temozolomide—melanoma	7e-05	0.00078	CcSEcCtD
Imiquimod—Infection—Docetaxel—melanoma	7e-05	0.000779	CcSEcCtD
Imiquimod—Vomiting—Carmustine—melanoma	6.97e-05	0.000776	CcSEcCtD
Imiquimod—Nausea—Dactinomycin—melanoma	6.95e-05	0.000775	CcSEcCtD
Imiquimod—Shock—Docetaxel—melanoma	6.93e-05	0.000772	CcSEcCtD
Imiquimod—Rash—Carmustine—melanoma	6.91e-05	0.00077	CcSEcCtD
Imiquimod—Nervous system disorder—Docetaxel—melanoma	6.91e-05	0.000769	CcSEcCtD
Imiquimod—Dermatitis—Carmustine—melanoma	6.9e-05	0.000769	CcSEcCtD
Imiquimod—Tachycardia—Docetaxel—melanoma	6.87e-05	0.000766	CcSEcCtD
Imiquimod—Headache—Carmustine—melanoma	6.87e-05	0.000765	CcSEcCtD
Imiquimod—Skin disorder—Docetaxel—melanoma	6.84e-05	0.000762	CcSEcCtD
Imiquimod—Vomiting—Temozolomide—melanoma	6.73e-05	0.00075	CcSEcCtD
Imiquimod—Anorexia—Docetaxel—melanoma	6.71e-05	0.000748	CcSEcCtD
Imiquimod—Rash—Temozolomide—melanoma	6.68e-05	0.000744	CcSEcCtD
Imiquimod—Dermatitis—Temozolomide—melanoma	6.67e-05	0.000743	CcSEcCtD
Imiquimod—Headache—Temozolomide—melanoma	6.63e-05	0.000739	CcSEcCtD
Imiquimod—Nausea—Carmustine—melanoma	6.51e-05	0.000725	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Docetaxel—melanoma	6.42e-05	0.000715	CcSEcCtD
Imiquimod—Insomnia—Docetaxel—melanoma	6.37e-05	0.00071	CcSEcCtD
Imiquimod—Paraesthesia—Docetaxel—melanoma	6.32e-05	0.000704	CcSEcCtD
Imiquimod—Nausea—Temozolomide—melanoma	6.29e-05	0.000701	CcSEcCtD
Imiquimod—Dyspnoea—Docetaxel—melanoma	6.28e-05	0.000699	CcSEcCtD
Imiquimod—Somnolence—Docetaxel—melanoma	6.26e-05	0.000697	CcSEcCtD
Imiquimod—Dyspepsia—Docetaxel—melanoma	6.2e-05	0.000691	CcSEcCtD
Imiquimod—Decreased appetite—Docetaxel—melanoma	6.12e-05	0.000682	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Docetaxel—melanoma	6.08e-05	0.000677	CcSEcCtD
Imiquimod—Fatigue—Docetaxel—melanoma	6.07e-05	0.000676	CcSEcCtD
Imiquimod—Pain—Docetaxel—melanoma	6.02e-05	0.000671	CcSEcCtD
Imiquimod—Feeling abnormal—Docetaxel—melanoma	5.8e-05	0.000646	CcSEcCtD
Imiquimod—Gastrointestinal pain—Docetaxel—melanoma	5.76e-05	0.000642	CcSEcCtD
Imiquimod—Abdominal pain—Docetaxel—melanoma	5.57e-05	0.00062	CcSEcCtD
Imiquimod—Body temperature increased—Docetaxel—melanoma	5.57e-05	0.00062	CcSEcCtD
Imiquimod—Hypersensitivity—Docetaxel—melanoma	5.19e-05	0.000578	CcSEcCtD
Imiquimod—TLR7—Immune System—AKT3—melanoma	5.07e-05	0.000716	CbGpPWpGaD
Imiquimod—Asthenia—Docetaxel—melanoma	5.05e-05	0.000563	CcSEcCtD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—melanoma	5.04e-05	0.000712	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	5.03e-05	0.00071	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CASP8—melanoma	5e-05	0.000706	CbGpPWpGaD
Imiquimod—Pruritus—Docetaxel—melanoma	4.98e-05	0.000555	CcSEcCtD
Imiquimod—TLR7—Immune System—IFNA2—melanoma	4.95e-05	0.0007	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HLA-A—melanoma	4.9e-05	0.000692	CbGpPWpGaD
Imiquimod—TLR8—Immune System—RAC1—melanoma	4.88e-05	0.00069	CbGpPWpGaD
Imiquimod—Diarrhoea—Docetaxel—melanoma	4.82e-05	0.000537	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—CTNNB1—melanoma	4.81e-05	0.00068	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—MAP2K1—melanoma	4.75e-05	0.000671	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PIK3CD—melanoma	4.72e-05	0.000667	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CDKN1A—melanoma	4.7e-05	0.000664	CbGpPWpGaD
Imiquimod—TLR7—Immune System—SOCS1—melanoma	4.69e-05	0.000663	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—PTEN—melanoma	4.69e-05	0.000663	CbGpPWpGaD
Imiquimod—TLR7—Immune System—S100B—melanoma	4.68e-05	0.000662	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—NFKB1—melanoma	4.67e-05	0.000659	CbGpPWpGaD
Imiquimod—Dizziness—Docetaxel—melanoma	4.66e-05	0.000519	CcSEcCtD
Imiquimod—TLR7—Immune System—ITGB1—melanoma	4.6e-05	0.00065	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDK2—melanoma	4.6e-05	0.00065	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—FGF2—melanoma	4.52e-05	0.000638	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	4.51e-05	0.000638	CbGpPWpGaD
Imiquimod—Vomiting—Docetaxel—melanoma	4.48e-05	0.000499	CcSEcCtD
Imiquimod—TLR7—Immune System—ERBB4—melanoma	4.48e-05	0.000633	CbGpPWpGaD
Imiquimod—TLR8—Immune System—TLR4—melanoma	4.48e-05	0.000633	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HLA-DRB1—melanoma	4.47e-05	0.000632	CbGpPWpGaD
Imiquimod—Rash—Docetaxel—melanoma	4.44e-05	0.000495	CcSEcCtD
Imiquimod—Dermatitis—Docetaxel—melanoma	4.44e-05	0.000494	CcSEcCtD
Imiquimod—Headache—Docetaxel—melanoma	4.41e-05	0.000491	CcSEcCtD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	4.3e-05	0.000607	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD86—melanoma	4.29e-05	0.000607	CbGpPWpGaD
Imiquimod—TLR8—Immune System—ICAM1—melanoma	4.29e-05	0.000607	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—BCL2—melanoma	4.29e-05	0.000606	CbGpPWpGaD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—melanoma	4.24e-05	0.000599	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—MDM2—melanoma	4.23e-05	0.000597	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HGF—melanoma	4.21e-05	0.000595	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—AKR1B10—melanoma	4.19e-05	0.000593	CbGpPWpGaD
Imiquimod—Nausea—Docetaxel—melanoma	4.18e-05	0.000466	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—NRAS—melanoma	4.18e-05	0.000591	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—ERBB2—melanoma	4.17e-05	0.000589	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CSF2—melanoma	4.16e-05	0.000588	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD8A—melanoma	4.16e-05	0.000588	CbGpPWpGaD
Imiquimod—TLR7—Immune System—FGF1—melanoma	4.16e-05	0.000588	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	4.14e-05	0.000585	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD80—melanoma	4.13e-05	0.000584	CbGpPWpGaD
Imiquimod—TLR8—Immune System—KIT—melanoma	4.12e-05	0.000583	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PIK3CB—melanoma	4.11e-05	0.000581	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CD4—melanoma	4.1e-05	0.00058	CbGpPWpGaD
Imiquimod—TLR8—Immune System—EGF—melanoma	4.08e-05	0.000576	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PDGFRA—melanoma	4.03e-05	0.00057	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—MAPK3—melanoma	4.01e-05	0.000566	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HLA-B—melanoma	4e-05	0.000566	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PRKCA—melanoma	3.99e-05	0.000564	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MAP2K2—melanoma	3.9e-05	0.000551	CbGpPWpGaD
Imiquimod—CYP1A2—Melatonin metabolism and effects—NFKB1—melanoma	3.9e-05	0.000551	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	3.88e-05	0.000548	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CDKN1B—melanoma	3.86e-05	0.000545	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CASP8—melanoma	3.84e-05	0.000543	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—MAPK1—melanoma	3.81e-05	0.000539	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—EGFR—melanoma	3.81e-05	0.000539	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CDH1—melanoma	3.8e-05	0.000536	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—RB1—melanoma	3.78e-05	0.000534	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HLA-A—melanoma	3.71e-05	0.000524	CbGpPWpGaD
Imiquimod—TLR7—Immune System—RAC1—melanoma	3.7e-05	0.000523	CbGpPWpGaD
Imiquimod—TLR8—Immune System—MAP2K1—melanoma	3.65e-05	0.000516	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CTNNB1—melanoma	3.65e-05	0.000515	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PIK3CD—melanoma	3.63e-05	0.000512	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MAP2K1—melanoma	3.62e-05	0.000511	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—KRAS—melanoma	3.6e-05	0.000509	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—ACER3—melanoma	3.59e-05	0.000507	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CDKN1A—melanoma	3.56e-05	0.000503	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PTEN—melanoma	3.55e-05	0.000502	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—NFKB1—melanoma	3.54e-05	0.0005	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	3.48e-05	0.000492	CbGpPWpGaD
Imiquimod—TLR8—Immune System—FGF2—melanoma	3.47e-05	0.000491	CbGpPWpGaD
Imiquimod—TLR7—Immune System—TLR4—melanoma	3.39e-05	0.00048	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HLA-DRB1—melanoma	3.39e-05	0.000479	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—PIK3CA—melanoma	3.31e-05	0.000467	CbGpPWpGaD
Imiquimod—TLR8—Immune System—BCL2—melanoma	3.3e-05	0.000466	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IFNG—melanoma	3.27e-05	0.000462	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ICAM1—melanoma	3.25e-05	0.00046	CbGpPWpGaD
Imiquimod—TLR8—Immune System—MDM2—melanoma	3.25e-05	0.000459	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—melanoma	3.24e-05	0.000458	CbGpPWpGaD
Imiquimod—CYP1A2—Tryptophan metabolism—MDM2—melanoma	3.22e-05	0.000455	CbGpPWpGaD
Imiquimod—TLR8—Immune System—ERBB2—melanoma	3.2e-05	0.000453	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—NRAS—melanoma	3.17e-05	0.000448	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PIK3CB—melanoma	3.16e-05	0.000447	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD4—melanoma	3.15e-05	0.000446	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD80—melanoma	3.13e-05	0.000443	CbGpPWpGaD
Imiquimod—TLR7—Immune System—KIT—melanoma	3.13e-05	0.000442	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—melanoma	3.1e-05	0.000439	CbGpPWpGaD
Imiquimod—TLR7—Immune System—EGF—melanoma	3.09e-05	0.000437	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—HRAS—melanoma	3.06e-05	0.000433	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—MAPK3—melanoma	3.04e-05	0.000429	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CDKN1B—melanoma	2.97e-05	0.000419	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—melanoma	2.94e-05	0.000416	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—melanoma	2.94e-05	0.000416	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—IL6—melanoma	2.93e-05	0.000414	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CASP8—melanoma	2.91e-05	0.000411	CbGpPWpGaD
Imiquimod—CYP1A2—Arachidonic acid metabolism—PTGS2—melanoma	2.9e-05	0.00041	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL2—melanoma	2.9e-05	0.00041	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—MAPK1—melanoma	2.89e-05	0.000408	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—EGFR—melanoma	2.89e-05	0.000408	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—melanoma	2.88e-05	0.000407	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDH1—melanoma	2.88e-05	0.000407	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP17A1—melanoma	2.85e-05	0.000403	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP17A1—melanoma	2.81e-05	0.000397	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CTNNB1—melanoma	2.8e-05	0.000396	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MAP2K1—melanoma	2.77e-05	0.000391	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PIK3CD—melanoma	2.75e-05	0.000388	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CDKN1A—melanoma	2.74e-05	0.000387	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PTEN—melanoma	2.73e-05	0.000386	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—KRAS—melanoma	2.73e-05	0.000386	CbGpPWpGaD
Imiquimod—TLR8—Immune System—NFKB1—melanoma	2.72e-05	0.000384	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—melanoma	2.71e-05	0.000384	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—AKT1—melanoma	2.7e-05	0.000382	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—melanoma	2.69e-05	0.000381	CbGpPWpGaD
Imiquimod—TLR7—Immune System—FGF2—melanoma	2.63e-05	0.000372	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PIK3CA—melanoma	2.51e-05	0.000354	CbGpPWpGaD
Imiquimod—TLR7—Immune System—BCL2—melanoma	2.5e-05	0.000353	CbGpPWpGaD
Imiquimod—CYP3A4—Tryptophan metabolism—MDM2—melanoma	2.49e-05	0.000351	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IFNG—melanoma	2.48e-05	0.00035	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MDM2—melanoma	2.46e-05	0.000348	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—melanoma	2.45e-05	0.000346	CbGpPWpGaD
Imiquimod—TLR8—Immune System—STAT3—melanoma	2.44e-05	0.000345	CbGpPWpGaD
Imiquimod—TLR8—Immune System—NRAS—melanoma	2.44e-05	0.000344	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ERBB2—melanoma	2.43e-05	0.000343	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—melanoma	2.42e-05	0.000341	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP1B1—melanoma	2.4e-05	0.000339	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PIK3CB—melanoma	2.4e-05	0.000339	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD4—melanoma	2.39e-05	0.000338	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP1B1—melanoma	2.37e-05	0.000334	CbGpPWpGaD
Imiquimod—TLR8—Immune System—MAPK3—melanoma	2.33e-05	0.00033	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—HRAS—melanoma	2.32e-05	0.000328	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MYC—melanoma	2.25e-05	0.000318	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDKN1B—melanoma	2.25e-05	0.000318	CbGpPWpGaD
Imiquimod—TLR8—Immune System—MAPK1—melanoma	2.22e-05	0.000314	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—IL6—melanoma	2.22e-05	0.000314	CbGpPWpGaD
Imiquimod—TLR8—Immune System—EGFR—melanoma	2.22e-05	0.000314	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—melanoma	2.2e-05	0.000311	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—melanoma	2.2e-05	0.000311	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—melanoma	2.2e-05	0.000311	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL2—melanoma	2.2e-05	0.000311	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP17A1—melanoma	2.2e-05	0.000311	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIP4K2A—melanoma	2.17e-05	0.000307	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP17A1—melanoma	2.17e-05	0.000307	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CTNNB1—melanoma	2.12e-05	0.0003	CbGpPWpGaD
Imiquimod—TLR8—Immune System—KRAS—melanoma	2.1e-05	0.000296	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	2.1e-05	0.000296	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—TNF—melanoma	2.1e-05	0.000296	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—melanoma	2.08e-05	0.000294	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDKN1A—melanoma	2.07e-05	0.000293	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PTEN—melanoma	2.07e-05	0.000293	CbGpPWpGaD
Imiquimod—TLR7—Immune System—NFKB1—melanoma	2.06e-05	0.000291	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—AKT1—melanoma	2.05e-05	0.000289	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PIK3CA—melanoma	1.93e-05	0.000272	CbGpPWpGaD
Imiquimod—TLR7—Immune System—STAT3—melanoma	1.85e-05	0.000262	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP1B1—melanoma	1.85e-05	0.000262	CbGpPWpGaD
Imiquimod—TLR7—Immune System—NRAS—melanoma	1.85e-05	0.000261	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP1B1—melanoma	1.83e-05	0.000258	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CUBN—melanoma	1.82e-05	0.000257	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HRAS—melanoma	1.78e-05	0.000252	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MAPK3—melanoma	1.77e-05	0.00025	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—melanoma	1.77e-05	0.00025	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL6—melanoma	1.71e-05	0.000241	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—GPAM—melanoma	1.7e-05	0.00024	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MAPK1—melanoma	1.68e-05	0.000238	CbGpPWpGaD
Imiquimod—TLR7—Immune System—EGFR—melanoma	1.68e-05	0.000238	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ACER3—melanoma	1.6e-05	0.000226	CbGpPWpGaD
Imiquimod—TLR7—Immune System—KRAS—melanoma	1.59e-05	0.000225	CbGpPWpGaD
Imiquimod—TLR8—Immune System—AKT1—melanoma	1.57e-05	0.000222	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—UGT2B10—melanoma	1.46e-05	0.000207	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PIK3CA—melanoma	1.46e-05	0.000206	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	1.44e-05	0.000204	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HS3ST5—melanoma	1.36e-05	0.000192	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HRAS—melanoma	1.35e-05	0.000191	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL6—melanoma	1.29e-05	0.000183	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ACER3—melanoma	1.23e-05	0.000174	CbGpPWpGaD
Imiquimod—TLR7—Immune System—AKT1—melanoma	1.19e-05	0.000169	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—UGT2B10—melanoma	1.13e-05	0.000159	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.09e-05	0.000155	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HS3ST5—melanoma	1.05e-05	0.000148	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PLCB4—melanoma	1.03e-05	0.000146	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—FASN—melanoma	1.01e-05	0.000143	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC6A11—melanoma	9.69e-06	0.000137	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIP4K2A—melanoma	9.69e-06	0.000137	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—MTAP—melanoma	9.42e-06	0.000133	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	9.21e-06	0.00013	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PHGDH—melanoma	8.4e-06	0.000119	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—LUM—melanoma	8.4e-06	0.000119	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HPSE—melanoma	8.24e-06	0.000116	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CUBN—melanoma	8.08e-06	0.000114	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PLCB4—melanoma	7.95e-06	0.000112	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SDHD—melanoma	7.81e-06	0.00011	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—BSG—melanoma	7.81e-06	0.00011	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CSPG4—melanoma	7.81e-06	0.00011	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GPAM—melanoma	7.56e-06	0.000107	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC6A11—melanoma	7.48e-06	0.000106	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIP4K2A—melanoma	7.48e-06	0.000106	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—MTAP—melanoma	7.27e-06	0.000103	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—LUM—melanoma	6.48e-06	9.16e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PHGDH—melanoma	6.48e-06	9.16e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PLA2G6—melanoma	6.43e-06	9.09e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HPSE—melanoma	6.36e-06	8.98e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CUBN—melanoma	6.24e-06	8.82e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SDHD—melanoma	6.03e-06	8.52e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—BSG—melanoma	6.03e-06	8.52e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CSPG4—melanoma	6.03e-06	8.52e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GPAM—melanoma	5.84e-06	8.25e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—VCAN—melanoma	5.78e-06	8.16e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.47e-06	7.73e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	5.28e-06	7.46e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PLA2G6—melanoma	4.96e-06	7.01e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP17A1—melanoma	4.87e-06	6.89e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.81e-06	6.79e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	4.74e-06	6.71e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GNA11—melanoma	4.6e-06	6.5e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—FASN—melanoma	4.5e-06	6.36e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—VCAN—melanoma	4.46e-06	6.3e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC5A5—melanoma	4.43e-06	6.26e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GNAQ—melanoma	4.28e-06	6.05e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CD44—melanoma	4.28e-06	6.05e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.19e-06	5.92e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.15e-06	5.87e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP1B1—melanoma	4.1e-06	5.8e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP17A1—melanoma	3.76e-06	5.31e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.62e-06	5.12e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GNA11—melanoma	3.55e-06	5.02e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—FASN—melanoma	3.48e-06	4.91e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC5A5—melanoma	3.42e-06	4.83e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ABCB1—melanoma	3.38e-06	4.77e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GNAQ—melanoma	3.3e-06	4.67e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CD44—melanoma	3.3e-06	4.67e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP1B1—melanoma	3.17e-06	4.47e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PRKCA—melanoma	3.11e-06	4.39e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ERCC2—melanoma	3.08e-06	4.36e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ABCB1—melanoma	2.61e-06	3.68e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.55e-06	3.61e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CG—melanoma	2.43e-06	3.44e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PRKCA—melanoma	2.4e-06	3.39e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ERCC2—melanoma	2.38e-06	3.36e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PPARG—melanoma	2.35e-06	3.32e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CD—melanoma	2.14e-06	3.02e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALB—melanoma	2.11e-06	2.99e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CG—melanoma	1.88e-06	2.66e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CB—melanoma	1.87e-06	2.64e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTGS2—melanoma	1.85e-06	2.61e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PPARG—melanoma	1.81e-06	2.56e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CD—melanoma	1.65e-06	2.33e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALB—melanoma	1.63e-06	2.3e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTEN—melanoma	1.61e-06	2.28e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CB—melanoma	1.44e-06	2.03e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTGS2—melanoma	1.43e-06	2.02e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTEN—melanoma	1.24e-06	1.76e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CA—melanoma	1.14e-06	1.61e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—AKT1—melanoma	9.29e-07	1.31e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CA—melanoma	8.78e-07	1.24e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—AKT1—melanoma	7.17e-07	1.01e-05	CbGpPWpGaD
